Copyright: ©Author(s) 2026.
World J Gastroenterol. Jan 14, 2027; 33(2): 124393
Published online Jan 14, 2027. doi: 10.3748/wjg.124393
Published online Jan 14, 2027. doi: 10.3748/wjg.124393
Figure 1 Computed tomography revealing cancer of the descending colon and sigmoid colon at different times.
A: Whole abdominal plain computed tomography (CT) following admission (January 28, 2025); B: Enhanced abdominal CT following admission (January 29, 2025); C: Enhanced abdominal CT one month after treatment with the combination of tislelizumab and bevacizumab (May 6, 2025); D: Enhanced abdominal CT three months after targeted immunotherapy (July 16, 2025); E: Enhanced abdominal CT five months after targeted immunotherapy (September 17, 2025).
- Citation: Chen YF, Huang C, Chen ZJ, Wang ZH. Significant response to tislelizumab plus bevacizumab in a patient with microsatellite instability-high colon cancer: A case report and review of literature. World J Gastroenterol 2027; 33(2): 124393
- URL: https://www.wjgnet.com/1007-9327/full/v33/i2/124393.htm
- DOI: https://dx.doi.org/10.3748/wjg.124393